16:01:28 Europe / Stockholm

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-16 Extra Bolagsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 Ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 Ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.

Kontakt

Asle Steiestøl Wingsternes

Head of Communications & Public Affairs
Mobile: +47 41 61 42 52
Email: asle.wingsternes@lifecare.no

Kontakt

Joacim Holter

CEO
Mobile: + 47 40 05 90 40
Email: joacim.holter@lifecare.no

Kontakt

Aslak Fisketjønn

Controller
Mobile: +47 95 88 73 51
Email: aslak.fisketjonn@lifecare.no

Filter arrow-icon
År arrow-icon
Typ arrow-icon
Språk arrow-icon
2024-05-16 13:25:00 Minutes from Extraordinary General Meeting pdf download pdf download
2024-05-07 08:00:00 Lifecare Q1 2024 report and webcast pdf download
2024-05-02 20:41:00 Extraordinary General Meeting pdf download pdf download
2024-04-30 15:40:00 Minutes from Annual General Meeting pdf download pdf download
2024-04-29 08:00:00 LIFE – Lifecare becomes majority shareholder in RemovAid pdf download
2024-04-26 13:29:00 LIFE – Strategic investment in RemoveAid AS pdf download
2024-04-25 20:00:00 Lifecare AS: Proposed partially underwritten rights issue pdf download
2024-04-16 11:32:00 Annual General Meeting pdf download pdf download
2024-04-16 08:00:00 LIFE: Presentation at MARSS 2024 pdf download
2024-04-09 23:03:00 LIFE - Lifecare’s Annual Report 2023 pdf download zip download
2024-04-03 07:55:00 LIFE - Breakthrough: Reaching target for pilot production pdf download
2024-03-06 08:00:00 LIFE: Poster presentations at ATTD 2024 in Firenze pdf download pdf download pdf download pdf download
2024-03-05 08:00:00 LIFE: Placing purchase order for cleanroom pdf download
2024-02-27 08:00:00 Lifecare Q4 2023 Report – Steady course pdf download
2024-02-26 08:00:00 Lifecare Q4 2023 report and webcast pdf download
2024-02-01 08:00:00 LIFE – Appointment of Production Manager pdf download
2024-01-24 16:03:30 LIFE: Financial calendar
2024-01-24 16:03:30 LIFE: Finansiell kalender
2024-01-09 08:00:00 LIFE – Successfully ISO 13485 certified pdf download
2024-01-03 08:00:00 LIFE: Letter from CEO - Happy New Year pdf download
2023-12-15 17:53:00 LIFE: CSO - Switch from consultancy agreement to employee pdf download
2023-11-20 08:00:00 LIFE: Successful ISO 13485 audit pdf download
2023-11-14 08:00:00 LIFE: Lifecare Q3 2023 Report pdf download
2023-11-13 08:00:00 Lifecare Q3 2023 report and webcast pdf download
2023-11-06 15:37:00 Lifecare – New share capital registered pdf download
2023-10-31 13:02:17 LIFE: Financial calendar
2023-10-26 08:00:00 Lifecare - Sanofi Product Development Agreement Update
2023-10-19 21:17:07 Lifecare - Successful completion of private placement
2023-10-19 16:30:00 Lifecare - Contemplated private placement
2023-10-17 08:00:00 LIFE: Confirmation from Norwegian Medicines Agency